Akut mieloid leukémia (AML): vizsgálatok itt: Kína
226 trials · From ClinicalTrials.gov, checked 2026. november 18.. Ask the study team whether a trial fits you.
- 2. fázisNot yet taking people in KínaSelinexor Combined With Venetoclax Maintenance Therapy After Allo-HSCT
- Where
- Shanghai
- Életkor
- 18 év to 75 év
- People
- 73
- Run by
- Ruijin Hospital
See details and how to joinNCT06765928 - 4. fázisNot yet taking people in KínaCLAG+VEN vs CLAG in the Treatment of Relapsed/Refractory AML
- Where
- Guangzhou
- Életkor
- 18 év to 65 év
- People
- 172
- Run by
- Nanfang Hospital, Southern Medical University
See details and how to joinNCT06763666 - Korai 1. fázisTaking peopleEvaluation of the Safety and Efficacy of Human CI-135 (FLT3) Targeted CAR-T Cells Injection for Subjects with Relapsed/Refractory Acute Myeloid Leukemia
- Where
- Suzhou
- Életkor
- 18 év to 70 év
- People
- 7
- Run by
- Hrain Biotechnology Co., Ltd.
See details and how to joinNCT06760260 - Korai 1. fázisTaking peopleA Clinical Study to Explore the Safety and Efficacy of CD33 CAR-T Cell in Relapsed/Refractory Acute Myeloid Leukemia
- Where
- Hangzhou
- Életkor
- 18 év and over
- People
- 27
- Run by
- Zhejiang University
See details and how to joinNCT06762132 - No phaseNot yet taking people in KínaImmediate Allogeneic Hematopoietic Stem Cell Transplantation Versus Re-treatment for Patients With High-Risk Acute Myeloid Leukemia
- Where
- Chengdu, Jinan, Shijiazhuang, Zhengzhou
- Életkor
- 18 év and over
- People
- 358
- Run by
- Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT06643195 - 2. fázisTaking peopleSafety and Efficacy of Mitoxantrone Hydrochloride Liposome Based DCMG Regimen for R/R AML
- Where
- Beijing
- Életkor
- 18 év to 75 év
- People
- 20
- Run by
- Beijing 302 Hospital
See details and how to joinNCT06741722 - 1/2. fázisTaking peopleBN104 in Combination With Chemotherapy or Targeted Agents for Acute Myeloid Leukemia
- Where
- Suzhou
- Életkor
- 18 év and over
- People
- 135
- Run by
- Chen Suning
See details and how to joinNCT06746519 - Korai 1. fázisNot yet taking people in KínaInduced Pluripotent Stem Cells Derived Natural Killer Cells Therapy for Refractory and Relaps Acute Myelogenous Leukemia
- Where
- Guangzhou
- Életkor
- 18 év to 80 év
- People
- 10
- Run by
- Guangzhou Ruixin Biotechnological Co., LTD
See details and how to joinNCT06702098 - 1/2. fázisTaking peopleSequential CAR-T Cells Targeting CD33/CD123 in Patients With Acute Myelocytic Leukemia AML
- Where
- Beijing
- Életkor
- 6 év to 90 év
- People
- 85
- Run by
- Essen Biotech
See details and how to joinNCT06420063 - No phaseTaking peopleVenetoclax Combined with Intensive Therapy for Acute Myeloid Leukemia Patients with Lower Early Peripheral Blast Clearance Rate After Standard Induction Therapy
- Where
- Nantong
- Életkor
- 18 év to 70 év
- People
- 83
- Run by
- Affiliated Hospital of Nantong University
See details and how to joinNCT06643962 - 2. fázisNot yet taking people in KínaMolecular Subtype Combined with Early Minimal Residual Disease to Optimize the Treatment of Newly Diagnosed Acute Myeloid Leukemia
- Where
- Shanghai
- Életkor
- 18 év to 59 év
- People
- 218
- Run by
- Ruijin Hospital
See details and how to joinNCT06652685 - Korai 1. fázisTaking peopleEX02 CAR-T Cells for Relapsed and Refractory Acute Myeloid Leukemia
- Where
- Hefei
- Életkor
- 18 év to 70 év
- People
- 9
- Run by
- Zhimin Zhai
See details and how to joinNCT06642025 - 2. fázisTaking peopleMitoxantrone Hydrochloride Liposome in Combination With Cytarabine and Venetoclax Regimen in Newly Diagnosed Elderly AML
- Where
- Hangzhou
- Életkor
- 60 év to 70 év
- People
- 42
- Run by
- First Affiliated Hospital of Zhejiang University
See details and how to joinNCT06621199 - 3. fázisNot yet taking people in KínaTwice-per-weekSelinexor, 2 Days Melphalan
- Where
- Chengdu, Jinan, Shijiazhuang, Zhengzhou
- Életkor
- 55 év and over
- People
- 126
- Run by
- Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT06613035 - 4. fázisTaking peopleRIC Allo-HSCT vs. Venetoclax-Based Consolidation in Elderly AML Patients After First CR
- Where
- Hangzhou
- Életkor
- 60 év to 75 év
- People
- 118
- Run by
- He Huang
See details and how to joinNCT06571825 - 2. fázisTaking peopleClinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML
- Where
- Beijing, Changsha, Guangzhou, Hefei, Jinan, Kaifeng, Nanning, Shanghai, Suzhou, Xuzhou, Zhengzhou
- Életkor
- Up to 18 év
- People
- 500
- Run by
- Children's Hospital of Soochow University
See details and how to joinNCT06221683 - 2. fázisTaking peopleSafety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation
- Where
- Changsha, Guangzhou, Hefei, Jinan, Kaifeng, Nanning, Shanghai, Suzhou, Xuzhou, Zhengzhou
- Életkor
- Up to 18 év
- People
- 50
- Run by
- Children's Hospital of Soochow University
See details and how to joinNCT06316960 - 2. fázisNot yet taking people in KínaCHG Combined With Venetoclax and Azacytidine in Newly Diagnosed AML
- Where
- Beijing
- Életkor
- 18 év and over
- People
- 85
- Run by
- Navy General Hospital, Beijing
See details and how to joinNCT06470841 - Korai 1. fázisNot yet taking people in KínaHema-NeoTIL01 Cell Infusion Therapy in Relapsed/Refractory Acute Leukemia
- Where
- Suzhou
- Életkor
- 18 év to 70 év
- People
- 20
- Run by
- The First Affiliated Hospital of Soochow University
See details and how to joinNCT06559644 - 1. fázisTaking peopleA Clinical Trial of TQB3455 Tablets in Patients With Hematological Malignancies
- Where
- Beijing, Chengdu, Harbin, Shanghai, Shijiazhuang, Tianjin
- Életkor
- 18 év and over
- People
- 100
- Run by
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
See details and how to joinNCT06550713 - 2/3. fázisCsak meghívásosVenetoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients
- Where
- Suzhou
- People
- 98
- Run by
- The First Affiliated Hospital of Soochow University
See details and how to joinNCT06544109 - 2. fázisTaking peopleVA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS
- Where
- Beijing
- Életkor
- 18 év to 70 év
- People
- 67
- Run by
- Beijing 302 Hospital
See details and how to joinNCT06536959 - No phaseTaking peopleClinical Trial Protocol for the Combined Use of VAG in the Treatment of ND-AML
- Where
- Huai'an
- Életkor
- 18 év to 75 év
- People
- 50
- Run by
- Yang Xiaotian
See details and how to joinNCT06536010 - No phaseTaking peopleIntensive Conditioning withTHI/Bu/Flu/Ara-C in Allo-HSCT for Myeloid Malignancies With Extramedullary Involvement
- Where
- Shanghai
- Életkor
- 18 év to 55 év
- People
- 50
- Run by
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
See details and how to joinNCT06111612 - No phaseTaking peopleMRD Response-adapted Allo-HSCT for Adverse-risk AML
- Where
- Beijing
- Életkor
- 16 év to 65 év
- People
- 178
- Run by
- Peking University People's Hospital
See details and how to joinNCT06301425